ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Hypothetical Dosage Question
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 134509" data-attributes="member: 13851"><p>Hard to believe you are following a trt protocol without even knowing where your SHBG sits.</p><p></p><p>Regarding hematocrit.....it is related to supra-physiological T levels resulting from one injecting larger doses of testosterone.</p><p></p><p>When injecting larger doses less frequently or running too high of a testosterone level (TT/FT) than one would be very prone to increased hematocrit.</p><p></p><p></p><p></p><p></p><p></p><p><span style="font-size: 26px"><strong>Erythrocytosis Following Testosterone Therapy</strong></span></p><p></p><p></p><p><span style="font-size: 22px"><strong>Considerations for Future Research</strong></span></p><p>A complete understanding of the molecular mechanisms of testosterone-induced erythrocytosis is essential to prevention and treatment of this common and significant adverse effect of TTh. <strong><span style="color: rgb(184, 49, 47)">Furthermore, the clinical implications of testosterone-induced erythrocytosis must be further elucidated to identify any actual risks associated with this condition. </span></strong>Alternative options for management of hypogonadal men, such as clomiphene citrate, human chorionic gonadotropin or aromatase inhibitors, may represent treatment options that can provide symptomatic benefit with rare supraphysiological T levels and low rates of erythrocytosis, though these therapies need further study in this context. <strong><span style="color: rgb(184, 49, 47)">Finally, randomized controlled trials are still needed in order to rigorously determine the effects of TTh on erythrocytosis, and the potential thromboembolic sequela that may result.</span></strong></p><p></p><p></p><p></p><p></p><p><span style="font-size: 22px"><strong>Conclusions</strong></span></p><p>Erythrocytosis is often a limiting variable in patients on TTh. <strong><span style="color: rgb(184, 49, 47)">Direct</span> and <span style="color: rgb(184, 49, 47)">indirect effects </span>related to<span style="color: rgb(184, 49, 47)"> supraphysiologic T levels are thought</span> to mediate the effects on <span style="color: rgb(184, 49, 47)">erythrocytosis</span>. </strong><span style="color: rgb(0, 0, 0)"><strong>The </strong></span><span style="color: rgb(184, 49, 47)"><strong>true mechanism</strong></span><span style="color: rgb(0, 0, 0)"><strong> of erythrocytosis and its role on thromboembolic events </strong></span><span style="color: rgb(184, 49, 47)"><strong>remains unclear</strong></span><span style="color: rgb(0, 0, 0)"><strong>,</strong></span> though few data support an increased risk of CV events resulting from testosterone-induced erythrocytosis. Large multicenter randomized controlled trials are required to study TTh, its effects on Hb and Hct, and the clinical significance of treatment induced elevations in red blood cell mass.</p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p>[ATTACH=full]6639[/ATTACH]</p><p></p><p></p><p> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690890/figure/F1/" target="_blank">Figure 1</a> illustrates the proposed direct and indirect effects of testosterone on erythropoiesis.</p></blockquote><p></p>
[QUOTE="madman, post: 134509, member: 13851"] Hard to believe you are following a trt protocol without even knowing where your SHBG sits. Regarding hematocrit.....it is related to supra-physiological T levels resulting from one injecting larger doses of testosterone. When injecting larger doses less frequently or running too high of a testosterone level (TT/FT) than one would be very prone to increased hematocrit. [SIZE=26px][B]Erythrocytosis Following Testosterone Therapy[/B][/SIZE] [SIZE=22px][B]Considerations for Future Research[/B][/SIZE] A complete understanding of the molecular mechanisms of testosterone-induced erythrocytosis is essential to prevention and treatment of this common and significant adverse effect of TTh. [B][COLOR=rgb(184, 49, 47)]Furthermore, the clinical implications of testosterone-induced erythrocytosis must be further elucidated to identify any actual risks associated with this condition. [/COLOR][/B]Alternative options for management of hypogonadal men, such as clomiphene citrate, human chorionic gonadotropin or aromatase inhibitors, may represent treatment options that can provide symptomatic benefit with rare supraphysiological T levels and low rates of erythrocytosis, though these therapies need further study in this context. [B][COLOR=rgb(184, 49, 47)]Finally, randomized controlled trials are still needed in order to rigorously determine the effects of TTh on erythrocytosis, and the potential thromboembolic sequela that may result.[/COLOR][/B] [SIZE=22px][B]Conclusions[/B][/SIZE] Erythrocytosis is often a limiting variable in patients on TTh. [B][COLOR=rgb(184, 49, 47)]Direct[/COLOR] and [COLOR=rgb(184, 49, 47)]indirect effects [/COLOR]related to[COLOR=rgb(184, 49, 47)] supraphysiologic T levels are thought[/COLOR] to mediate the effects on [COLOR=rgb(184, 49, 47)]erythrocytosis[/COLOR]. [/B][COLOR=rgb(0, 0, 0)][B]The [/B][/COLOR][COLOR=rgb(184, 49, 47)][B]true mechanism[/B][/COLOR][COLOR=rgb(0, 0, 0)][B] of erythrocytosis and its role on thromboembolic events [/B][/COLOR][COLOR=rgb(184, 49, 47)][B]remains unclear[/B][/COLOR][COLOR=rgb(0, 0, 0)][B],[/B][/COLOR] though few data support an increased risk of CV events resulting from testosterone-induced erythrocytosis. Large multicenter randomized controlled trials are required to study TTh, its effects on Hb and Hct, and the clinical significance of treatment induced elevations in red blood cell mass. [ATTACH=full]6639[/ATTACH] [URL='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690890/figure/F1/']Figure 1[/URL] illustrates the proposed direct and indirect effects of testosterone on erythropoiesis. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Hypothetical Dosage Question
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top